Potential therapeutic use of PPARγ-programed human monocyte-derived dendritic cells in cancer vaccination therapy

Adrienn Gyöngyösi, László Nagy

Research output: Contribution to journalReview articlepeer-review

Abstract

Dendritic cells (DCs) can regulate all elements of the immune system, and therefore are an ideal target for vaccination. During the last two decades, as a result of extensive research, DCs became the primary target of antitumor vaccination as well. A critical issue of antitumor vaccination is the phenotype of the dendritic cell used. It has been recently shown that several nuclear hormone receptors, and amongst them the lipid-activated nuclear receptor and peroxisome proliferator-activated receptor gamma (PPAR γ), have important roles in effecting the immunophenotype of human dendritic cells. It regulates primarily lipid metabolism and via this it influences the immunophenotype of DCs by altering lipid antigen uptake, presentation, and also other immune functions. In this review, we summarize the principles of antitumor vaccination strategies and present our hypothesis on how PPAR γ -regulated processes might be involved and could be exploited in the design of vaccination strategies.

Original languageEnglish (US)
Article number473804
JournalPPAR Research
DOIs
StatePublished - 2008
Externally publishedYes

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Potential therapeutic use of PPARγ-programed human monocyte-derived dendritic cells in cancer vaccination therapy'. Together they form a unique fingerprint.

Cite this